ÂÜÀòÂÒÂ×

Bernard A. Fox PhD has extensive experience in the field of immunotherapy and cancer research. Bernard A. is currently the Co-Founder, President, and CEO of UbiVac, a clinical stage immuno-oncology company. At UbiVac, they are involved in the development and testing of therapeutic immunotherapy strategies to combat cancer and infectious diseases. Bernard A. has led the development of three immunotherapy platforms, including Dribbles, Nanoparticles coupled to mosaic HPV E6/E7 peptides, and a recombinant Cytomegalovirus vaccine vector.

Prior to their role at UbiVac, Bernard A. Fox worked as the Harder Family Endowed Chair for Cancer Research and Chief of Molecular and Tumor Immunology at the Robert W. Franz Cancer Research Center. Bernard A.'sgoals were to develop effective immunotherapies for mice and translate them into patients with cancer. Bernard A. also served as an Adjunct Professor in the Department of Molecular Microbiology and Immunology at OHSU, where they lectured on cancer immunotherapy.

In addition to their work in the industry, Bernard A. Fox has been actively involved in various organizations related to immunotherapy. Bernard A. has served as the Chair of the World Immunotherapy Council, a member of the Board of Directors for the Oregon Bioscience Association, and as an Ambassador for the Society for Immunotherapy of Cancer (SITC). Bernard A. has also held leadership positions within SITC, including President and Immediate Past President. Prior to the formation of SITC, they were the Vice President of the International Society for Biological Therapy of Cancer (iSBTc).

Bernard A. Fox has also held academic positions as a Guest Professor at Xian Jiaotung University in China and the Department of Surgery at Ludwig-Maximilians-University. Overall, their work experience reflects their dedication to advancing immunotherapy and cancer research through both industry and academic roles, as well as their involvement in various professional organizations.

Dr. Bernard A. Fox obtained their MS degree in Immunology from the University of Detroit Mercy, where they studied from 1975 to 1978. Bernard A. then pursued their PhD in Regulatory Cell Biology and Biophysics at Wayne State University from 1979 to 1985. Following this, Dr. Fox worked as a Staff Fellow in Cancer Immunotherapy at the National Cancer Institute, NIH, from 1985 to 1990.